Our Multi-specific Immune engager therapies (TriNKETs®)
& Novel CYTOKINEs
Dragonfly's 2 Proprietary Platforms
Patient Need
For example, T cell based cancer treatments have offered some patients with some indications, remarkable therapeutic benefits -- but little improvement, for many.
Natural Killer (NK) cells and cytokines are part of the body’s natural immune system, and can destroy disease cells across a very broad range of indications – from oncology and neuromuscular disease, to autoimmune and virology indications.
Dragonfly’s drugs are designed to have a distinct safety profile, offering a broad therapeutic window where patient benefits can be considerable, and the challenges of disease treatment are limited.
Dragonfly's TriNKETs® and Cytokines dramatically expand immunotherapy, providing more options for patients
Dragonfly’s TriNKETs® amplify the power of traditional immunotherapy by engaging both the adaptive and innate immune systems, directly and indirectly, with a single mechanism.
Our TriNKETs® potently stimulate both Natural Killer cells in the innate immune system, and CD8 T cells in the adaptive immune system, offering a distinctly powerful therapeutic agent with a refreshing safety profile, in a single drug.
Both Dragonfly’s TriNKETs® and CYTOKINEs are designed to work combinatorily with a wide range of other I/O drugs, as well as with other traditional treatment approaches such as, in oncology, ADCs, chemotherapy and radiation.
Dragonfly’s TriNKETs® and CYTOKINEs have extraordinary CMC profiles that allow them to titre well, purify simply, concentrate easily and be stable under a wide range of conditions.